NAD(P)H:quinone oxidoreductase Antibody

Biological Role of NAD(P)H:Quinone Oxidoreductase 1 (NQO1)

NQO1 is a 30–33 kDa flavoprotein that catalyzes the two-electron reduction of quinones and nitroaromatics using NAD(P)H as an electron donor . Key functions include:

• Antioxidant Defense: Protects against oxidative stress by reducing reactive quinones and preventing semi-quinone radical formation .

• Protein Stabilization: Binds and stabilizes tumor suppressors like p53, delaying proteasomal degradation .

• NAD+ Homeostasis: Modulates NAD+/NADH ratios, influencing DNA repair mechanisms via PARP and sirtuin activation .

• Disease Modulation: Linked to cardiovascular diseases, diabetic nephropathy, and cancer progression .

Cancer Biology

• Therapeutic Targeting: NQO1 overexpression in tumors correlates with poor prognosis. Antibodies identify NQO1-positive cells for targeted therapies like β-lapachone, which induces NAD+ depletion and necrosis in cancer .

• Biomarker Validation: Used to validate NQO1 as a biomarker in colorectal cancer (CRC) via immunohistochemistry (IHC) .

Metabolic and Cardiovascular Diseases

• Diabetic Nephropathy: NQO1 antibodies confirm its role in reducing oxidative stress and apoptosis by regulating Sirt1/NAD+ pathways .

• Atherosclerosis: Studies link NQO1 activity to reduced lipid peroxidation and inflammation in vascular tissues .

Table 2: Key Research Findings Using NQO1 Antibodies

Clinical and Therapeutic Implications

• Cancer Therapy: NQO1 bioactivates prodrugs like β-lapachone, causing selective cytotoxicity in NQO1-rich tumors .

• Oxidative Stress Disorders: Antibodies aid in tracking NQO1’s protective effects in diabetes and cardiovascular diseases .

Challenges and Future Directions

• Dual Roles in Cancer: NQO1 exhibits both tumor-suppressive (detoxification) and oncogenic (chemoresistance) behaviors .

• Antibody Specificity: Cross-reactivity with NQO2 or degraded isoforms necessitates rigorous validation .